Diagnostic and Prognostic Performance of the Modified Lumipulse pTau 181 Assay in Plasma for Alzheimer’s Disease

Recent advances demonstrate utility in blood‐based phosphorylated tau (pTau) as a diagnostic biomarker for Alzheimer’s disease (AD). While several platforms show high diagnostic and prognostic performance, most assays rely on antibody combinations that require long tau peptides for their detection. The Lumipulse G Plasma pTau 181 assay (Fujirebio) instead uses an antibody combination targeting epitopes proximal to Thr181 and therefore can detect shorter tau peptides. This allows for a wider array of expressed plasma pTau 181 peptides to be measured.